Published in Eur J Heart Fail on February 14, 2012
Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit? Neth Heart J (2013) 1.35
Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Fail (2015) 0.77
Ambulatory ECG-based T-wave alternans and heart rate turbulence can predict cardiac mortality in patients with myocardial infarction with or without diabetes mellitus. Cardiovasc Diabetol (2012) 0.77
Microvolt T-wave alternans in an unselected heart failure population: pros and cons. Eur J Heart Fail (2012) 0.76
Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients. Eur J Heart Fail (2012) 0.75
Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi? Eur J Heart Fail (2012) 0.75
Usefulness of microvolt T-wave alternans testing in the assessment of all-cause mortality and life-threatening ventricular arrhythmia risk in patients with left ventricular dysfunction. Arch Med Sci (2014) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Outcomes of elective induction of labour compared with expectant management: population based study. BMJ (2012) 3.07
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Potential impact of public access defibrillators on survival after out of hospital cardiopulmonary arrest: retrospective cohort study. BMJ (2002) 2.89
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
CRYSTMET: a database of the structures and powder patterns of metals and intermetallics. Acta Crystallogr B (2002) 2.76
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens (2010) 2.73
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J (2010) 2.68
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation (2009) 2.60
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol (2012) 2.60
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail (2009) 2.51
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol (2005) 2.43